Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
The financial generosity of the pharmaceutical industry to provide funding for medical education tempts a compromise of professional standards and ethics.
In April 2002, many pharmaceutical companies adopted PhRMA code, an attempt to self-regulate the pharmaceutical industry's marketing to physicians and other health care professionals.
An ethical case explores whether a medical student doing a radiology rotation has a duty to inform a patient whose chest x-ray shows bony metastases that was not caught by the original radiologist or mentioned in the ED chart.
An ethical case explores a 70-year-old man diagnosed with pancreatic cancer who wants to have his pacemaker turned off in order to hasten what he fears may be an unpleasant death.
An ethical case explores a 70-year-old man diagnosed with pancreatic cancer who wants to have his pacemaker turned off in order to hasten what he fears may be an unpleasant death.
Alan Heins, an emergency room physician honored by the AMA for his leadership abilities, believes time management and establishing priorities are essential in both medical school and scheduling work hours for physicians.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.